Maximum quantity allowed is 999
请选择数量
CAS RN: 15663-27-1 | 產品號碼: D3371
cis-Diammineplatinum(II) Dichloride
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | D3371 |
| 分子式 / 分子量 | H__6Cl__2N__2Pt = 300.05 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Moisture Sensitive |
| 包裝和容器 | 100MG-Glass Bottle with Plastic Insert （閲覽圖片）, 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 15663-27-1 |
| PubChem Substance ID | 87558796 |
| Merck Index(14) | 2317 |
產品規格
| Appearance | Light orange to Yellow to Green powder to crystal |
| Elemental analysis(Nitrogen) | 8.90 to 9.80 % |
性質
| 熔點 | 270 °C |
| Degree of solubility in water | 2,530 mg/l 25 °C |
| 溶解性（可溶於） | Dimethylformamide |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H300 : Fatal if swallowed. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H340 : May cause genetic defects. H350 : May cause cancer. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | TP2450000 |
運輸資料
| UN編號 | UN3288 |
| 類別 | 6.1 |
| 包裝類別 | II |
| HS編碼* | 2843.90-000 |
Application
Quorum sensing inhibitor
Reference
- The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors
Application
Platinum Coordination Complexes as Antitumor Agents
The development of platinum coordination complexes as antitumor agents began in the 1960s, and the highest antitumor activity was exhibited by cisplatin, approved by FDA in 1978. Improved versions carboplatin [C2043] and oxaliplatin [O0372] were developed to avoid the serious side effects and the problem with resistance associated with the use of cisplatin.1-5)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
Application
Reagent for renal failure model
References
- Cis-diamminedichloroplatinum (DDP) induced acute renal failure (ARF): attempts at amelioration
- S. Chopra, J. Kaufman, W. Flamenbaum, Clin. Exp. Dial. Apheresis. 1983, 7, 25.
- Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat: enzyme histochemical studies
- Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations
- T. W. Jones, S. Chopra, J. S. Kaufman, W. Flamenbaum, B. F. Trump, Lab. Invest. 1985, 52, 363.
- Protective effects of dithiocarbamates against renal toxicity of cis-diamminedichloroplatinum in rats
- Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity
- Effect of fructose-1,6-bisphosphate on the nephrotoxicity induced by cisplatin in rats
- Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystitis
Application
Reagent for nausea or vomiting model
References
- Cisplatin-induced emesis in the Ferret: a new animal model.
- A. P. Florczyk, J. E. Schurig, W. T. Bradner, Cancer Treat Rep. 1982, 66, 1, 187-189.
- The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential.
Application
Reviews on the Biochemical Mechanisms of Action of Cisplatin
References
- Structure, recognition, and processing of cisplatin-DNA adducts
- Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?
- Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance
- Cisplatin: mode of cytotoxic action and molecular basis of resistance
- Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
- G. Chu. J. Biol. Chem. 1994, 269, 787.
- Cellular processing of platinum anticancer drugs
考研文獻
文章/手冊
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。